Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NPI-001 tablets administered orally BID at escalating doses of 250 mg, 500 mg, and 750 mg for period of 12 months”In the company’s words, NCT07741526 on ClinicalTrials.gov
- Tested for
- Alzheimer´s Disease
- Main trialPhase 2
- “The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.”In the company’s words, NCT07741526 on ClinicalTrials.gov
Other drugs for Alzheimer´s Disease
- PembrolizumabMerck & Co. · Phase 3
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
Coming up1
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Apr 2027 | Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026